Amidst Strong Quarterly Growth, Novartis Receives FDA Complete Response Letter for Canakinumab 글 내용 전체보기
Immune Design Abandons Cancer Vaccine Program, Drops 20% of Workforce at Two U.S. Locations 글 내용 전체보기
AbbVie Invests $100 Million in Morphic Therapeutics to Develop Integrin Inhibitors for Fibrotic Diseases 글 내용 전체보기